Kent Meningitis Outbreak: Students Affected, Vaccine Questions & Symptoms

An outbreak of meningitis in Kent, south-east England, has tragically resulted in two deaths – a 21-year-old university student and an 18-year-old school pupil – and left eleven others hospitalised. The cases are linked to meningitis B, a particularly concerning strain as many young people are not routinely vaccinated against it. This outbreak has understandably raised questions about vaccine access and the risks faced by different age groups. To understand the situation, Madeleine Finlay recently spoke with Eliza Gil, a clinical lecturer specialising in infectious disease at the London School of Hygiene and Tropical Medicine.

Understanding Meningitis B and the Current Outbreak

Meningitis is an inflammation of the meninges – the protective membranes covering the brain and spinal cord. It can be caused by several different pathogens, including bacteria, viruses and fungi. Bacterial meningitis, like the current outbreak of meningitis B, is particularly serious and can lead to severe complications, including brain damage, hearing loss, and even death. The UK Health Security Agency (UKHSA) has confirmed a total of 15 cases in the Canterbury area of Kent, with four specifically identified as meningitis B infections. The BBC reports that hundreds of people are being urged to receive antibiotics as a preventative measure to limit further spread.

Who is Most Vulnerable? The Role of Vaccination History

A key factor in this outbreak is the age of those affected and their vaccination status. The meningitis B (MenB) vaccine was introduced into the UK’s routine immunisation schedule in September 2015, offered to babies born on or after July 1, 2015. In other words that a significant proportion of teenagers and young adults – those born before 2015 – will not have received the MenB vaccine unless they opted for private vaccination. Dr. Ellie Cannon, a GP, explained that it’s “very possible” that teenagers now will not have received the vaccine because it wasn’t part of the schedule when they were infants.

This lack of protection in older age groups is a critical element of the current concern. While the vaccine offers strong protection to those who receive it, the absence of widespread immunity leaves a vulnerable population susceptible to infection. It’s important to note that even with vaccination, no vaccine offers 100% protection, and breakthrough infections can still occur, though they are typically less severe.

How is Meningitis B Spread?

Meningitis B is spread through close personal contact. As Hugh Pym of the BBC explained, this can occur in crowded environments or close living arrangements, such as university halls of residence. Importantly, the infection can be spread by individuals who are not yet showing symptoms, making containment more challenging. While not as easily transmitted as illnesses like influenza or COVID-19, meningitis B can progress rapidly, turning “really quickly” into a serious health crisis, according to Pym.

Recognising the Symptoms: What to Look For

Early recognition of meningitis symptoms is crucial for prompt medical intervention. Symptoms can vary, but common signs include a high fever, severe headache, stiff neck, nausea, vomiting, sensitivity to light, and a characteristic rash that doesn’t fade when pressed (though this rash doesn’t always appear). Confusion, drowsiness, and seizures can also occur. It’s vital to seek immediate medical attention if you suspect meningitis. The Meningitis Now charity provides comprehensive information on symptoms and what to do if you’re concerned.

The Public Health Response and Antibiotic Prophylaxis

In response to the outbreak, public health officials are urging individuals who may have been in close contact with confirmed cases to seek antibiotics as a preventative measure – a process known as antibiotic prophylaxis. This aims to reduce the risk of infection in those exposed, even if they are not showing symptoms. However, it’s important to understand that antibiotics are only effective against bacterial meningitis and will not treat viral forms of the disease. Antibiotic prophylaxis is not a substitute for vaccination, but a short-term measure to control an outbreak.

Why Wasn’t the MenB Vaccine Rolled Out to Teenagers Earlier?

The decision to introduce the MenB vaccine into the routine schedule for infants in 2015 followed years of debate and evaluation. Concerns about cost-effectiveness and the potential for adverse reactions played a role in the initial delay. The Joint Committee on Vaccination and Immunisation (JCVI), the independent expert advisory body that makes recommendations on vaccination policy in the UK, continually reviews the evidence and updates its recommendations as recent data grow available. The current situation in Kent is likely to prompt a renewed review of the JCVI’s recommendations regarding MenB vaccination for older age groups.

Understanding Vaccine Schedules and Prioritisation

Vaccine schedules are carefully designed to provide protection at the ages when individuals are most vulnerable to specific diseases. For meningitis B, infants are at the highest risk in the first year of life, which is why the vaccine was initially targeted at this age group. Prioritisation decisions are often based on a complex assessment of disease burden, vaccine efficacy, cost-effectiveness, and potential impact on public health. These decisions are not taken lightly and are subject to ongoing scrutiny.

What Comes Next: Surveillance, Review, and Potential Policy Changes

The current outbreak will undoubtedly trigger a series of actions from public health authorities. Enhanced surveillance will be crucial to monitor the spread of infection and identify any further cases. The UKHSA will continue to investigate the outbreak to determine the source and risk factors. The JCVI will likely review the latest data and consider whether to revise its recommendations on MenB vaccination for teenagers and young adults. Any changes to the vaccination schedule would be based on a thorough assessment of the evidence and a careful consideration of the potential benefits and risks. Individuals should stay informed by checking official public health updates from the UK Health Security Agency and consulting with their healthcare providers.